Obsessive compulsive disorder.
BACKGROUND
Obsessions or compulsions that cause personal distress or social dysfunction affect about 1% of men and 2% of women. About half of people with obsessive compulsive disorder (OCD) have an episodic course, whereas the other half have continuous problems. Up to half of people show improvement of symptoms over time.


METHODS
We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of initial treatments for obsessive compulsive disorder in adults? What are the best forms of maintenance treatment for obsessive compulsive disorder in adults? What are the effects of treatments for obsessive compulsive disorder in adults who have not responded to initial treatment with serotonin reuptake inhibitors? We searched: Medline, Embase, The Cochrane Library and other important databases up to July 2006 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).


RESULTS
We found 55 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.


CONCLUSIONS
In this systematic review we present information relating to the effectiveness and safety of the following interventions: addition of antipsychotics to serotonin reuptake inhibitors; behavioural therapy alone or with serotonin reuptake inhibitors; cognitive therapy or cognitive behavioural therapy (alone or with serotonin reuptake inhibitors); electroconvulsive therapy; serotonin reuptake inhibitors (citalopram, clomipramine, fluoxetine, fluvoxamine, paroxetine, sertraline); and optimum duration of maintenance treatment.
Soomro
G Mustafa
GM
Section of Community Psychiatry, St George's Hospital Medical School, London, UK.
D009771:Obsessive-Compulsive Disorder; D014481:United States; D014486:United States Food and Drug Administration